Articles tagged with Vaccine Development
The University of Virginia has appointed Dr. Mark T. Esser as the inaugural head of its Manning Institute, a $350 million facility aimed at transforming healthcare and accelerating new treatments. Esser brings decades of experience in developing new medical breakthroughs and will foster an ecosystem of innovation to attract biotechnolo...
A new study reveals that the US national vaccine strategy saved more money than it spent on testing, buying and delivering COVID-19 vaccines after just one year. The analysis found that the vaccines reduced serious illness and deaths, resulting in significant cost savings.
Researchers at HKU and CVVT create a nasal spray vaccine offering single-dose protection against H5N1 infection, inducing comprehensive immunity in the upper respiratory tract. The vaccine's high safety profile and ability to curb viral transmission make it a critical reserve for future outbreaks.
A promising new target for a Lyme disease vaccine has emerged: the Lyme bacterial protein CspZ. Genetic engineering revealed hidden regions that trigger a strong immune response. The modified protein promotes continuous production of protective antibodies, reducing the need for booster shots.
Researchers at the University of Maryland discovered a way to predict treatment success for cutaneous leishmaniasis, a devastating skin infection. By analyzing a patient's immune system, they identified a distinctive pattern that distinguishes responders from non-responders, with 90% accuracy.
The Vaccine Innovation Center at Korea University's College of Medicine successfully held the 2025 Vaccine Expert Training Program, attended by over 380 experts and researchers from various fields. The program aims to foster domestic vaccine R&D experts and promote the development of commercially available vaccines.
Researchers at MIT have developed a method to mass manufacture nanoparticles that target cancer cells, eliminating the need for manual polymer mixing and streamlining production. This approach integrates good manufacturing practice (GMP)-compliant processes, making it suitable for large-scale production of cancer treatments.
The MOPEVACLAS vaccine candidate is being tested in a Phase I clinical trial for its safety and immune response in humans. The vaccine targets Lassa fever, a hemorrhagic disease responsible for thousands of deaths worldwide each year.
The University of Texas at Arlington expert discusses the state's largest outbreak in 30 years, with fewer people getting vaccinated contributing to its spread. The MMR vaccine is 97% effective against measles and has been proven safe despite misconceptions about its safety.
Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
A new reverse genetics system for African swine fever virus (ASFV) has been developed, enabling rapid vaccine development and research into the virus's biology. This technology can be adapted for other viruses, including lumpy skin disease, Zika, chikungunya, and Ebola viruses.
Researchers from La Jolla Institute for Immunology and UC San Diego discover Zika virus blocks dendritic cells' ability to alert T cells, while dengue virus stimulates pro-inflammatory cytokines, leading to a stronger but uncontrolled immune response. Understanding these differences is key to developing life-saving vaccines.
Researchers developed a universal vaccine that removes sugar molecules from coronavirus spike proteins, creating effective antibodies. The vaccine showed improved protection against various variants and potential applications for cancer treatment.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
Researchers have made progress in understanding how Streptococcus pneumoniae constructs its capsule, a critical target for vaccine development. The study identified three categories of transporters that facilitate sugar building block transport, with relaxed specificity transporters posing potential risks to bacterial growth.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
A study published in The Lancet Infectious Diseases found that a single dose of the Imvanex vaccine provides 84% protection against Mpox for HIV-negative individuals, but offers limited protection for those living with HIV. The study recommends that all at-risk groups, particularly those with HIV, receive two doses of the vaccine to ac...
A Phase 1 clinical trial is enrolling up to 55 healthy adults to test the safety and immunogenicity of a candidate Lassa vaccine. The trial aims to prevent Lassa fever, a viral hemorrhagic disease that can cause permanent hearing loss.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
A study has established the importance of immunoglobulin A in generating a response to pneumonia vaccines. The research found that poor regulation of gut microbiota can lead to an inadequate immune response, leaving individuals vulnerable to respiratory infections.
A major clinical trial has identified ensitrelvir as an effective medication to prevent symptomatic COVID-19 in people exposed within households. The trial showed a 67% reduction in risk of illness among participants taking the antiviral compared to those given a placebo.
A recent study by Oregon Health & Science University and Weill Cornell Medicine has found that CMV lacking a certain viral protein complex can still be transmitted and cause significant harm to the developing fetus. The research suggests that additional vaccine targets need to be identified and explored to provide superior protection.
Researchers at the University of Leeds have developed a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). VLPs mimic the outer protein shell of poliovirus but are empty inside, making them non-infectious yet capable of triggering an immune response.
A new study has discovered how antibodies help protect against Strep A infections and is contributing to the development of a Strep A vaccine. The research used the world's only human challenge model for Strep A, which uncovered the power and potential for this model to accelerate vaccine development.
The U.S. research ecosystem, fueled by high-performance computing, is facing a critical moment due to slow infrastructure growth and funding cuts. The National Science Foundation's staffing cuts will slow down the process of innovation, potentially harming the country's competitive edge in research.
Researchers have identified powerful antibodies capable of neutralizing a wide range of norovirus strains, paving the way for designing a broadly effective norovirus vaccine. The discovery brings us closer to a vaccine that could provide lasting protection and prevent devastating effects of norovirus outbreaks.
A risk prediction model was developed to identify patients unlikely to complete HPV vaccination. The model uses patient demographics and clinical characteristics to guide targeted interventions, increasing vaccination rates among high-risk groups.
A new TB vaccine candidate has shown complete protection and a superior immune response in nonhuman primates compared to the existing BCG vaccine. The delta sigH vaccine resulted in a more balanced and effective elimination of the bacteria, with lower levels of inflammation and a different type of interferon triggered.
Richard Willson, a University of Houston professor, has been elected Fellow of the Royal Society of Chemistry for his contributions to the chemical sciences. He has developed innovative methods to detect viruses and other biological threats using glow-in-the-dark nanoparticles.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
Lyme disease is a bacterial infection transmitted by ticks, posing an increasing threat in the U.S. Montana State University's Patrick Secor will study adaptations in Borrelia burgdorferi to illuminate how it circumvents its host's immune system. The goal is to discover new vaccine antigens and develop more effective treatments.
Researchers analyzed protein-coding RNA transcripts from single cells and lung fluid of infected pigs, monitoring immune cell alterations triggered by PRRSV strains of varying virulence. They found that high-virulence PRRSV caused severe lung damage and immune imbalance, while less virulent strains led to delayed lung damage with fewer...
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
A US clinical trial will assess the safety and efficacy of a nasal COVID-19 vaccine developed using technology from Washington University in St. Louis. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, aims to evaluate the vaccine's ability to induce strong immunity in the nose and upper respiratory tract.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
Researchers developed a new approach to quickly identify mutations that enable viral immune escape. By analyzing the effects of individual mutations in reverse, they found three key mutations in the spike protein responsible for immune evasion.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
Researchers developed MUNIS, a deep learning tool that predicts CD8+ T cell epitopes with high accuracy, potentially accelerating vaccine development. The tool was validated using experimental data from influenza, HIV, and EBV, demonstrating its potential to streamline vaccine design.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers develop BEND lipids to improve LNP mRNA delivery and gene editing by breaking through the endosomal membrane. The new lipids outperform existing LNPs used in COVID-19 vaccines, with improved efficacy rates up to tenfold.
Researchers at the University of Queensland have identified a new henipavirus, Camp Hill virus, in shrews in Alabama, USA. The discovery suggests these viruses may be more globally distributed than previously thought, with implications for human health and vaccine development.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
A novel diagnostic system called TwinDemic Detection offers simultaneous and rapid detection of SARS-CoV-2 and influenza A virus. The system has a detection limit of 0.46 picomolar for CoV and 0.39 pM for IAV, correctly predicting positive and negative samples in high percentages.
Researchers at the University of São Paulo's Medical School have developed a COVID-19 vaccine using virus-like particles (VLPs), which proved highly protective, safe, and versatile in animal trials. The vaccine can be easily updated to combat variants of concern without requiring an adjuvant.
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
Scientists discovered that T cells can prevent acute viral infections, challenging traditional views on sterilising immunity and herd immunity. The study found that T cells controlled viral loads and antibodies produced, and were effective in preventing infection to undetectable levels in some participants.
Researchers at the University of Gothenburg have discovered an antibody-like molecule, E10, that can protect mice from various influenza viruses. The molecule targets a conserved part of the virus's surface protein shared across multiple influenza types, providing effective protection against seasonal epidemics.
Researchers at NIH have identified a novel class of anti-malaria antibodies that target previously untargeted regions of the parasite. These antibodies have shown promise in providing protection against malaria parasites in animal models and could lead to new prevention methods.
Researchers developed AI-driven therapeutic platform mimicking viral structures to deliver therapeutic genes to target cells. The innovative approach achieved precise symmetrical structures and effectively delivered payloads, paving the way for breakthroughs in gene therapies and next-generation vaccines.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
A live-attenuated vaccine against Lassa virus has been developed and shown to be safe and 100% effective in protecting guinea pigs from the virus. The vaccine was created by modifying the genome of the virus to prevent it from causing disease, making it a promising candidate for future clinical trials.
EBViously aims to prevent infectious mononucleosis and secondary diseases such as ME/CFS, while also protecting against certain types of cancer. The company's innovative vaccine candidate uses virus-like particles derived from EBV to trigger a targeted immune response.
Researchers at Washington University in St. Louis are developing vaccines to target misfolded proteins in the brain, with a focus on preventing inflammation and using peptide nanofibers. The goal is to prevent dementia by training the immune system against amyloid beta and tau proteins.
Researchers created an advanced computational model to optimize maternal vaccine design and protect high-risk populations. The model helps reveal which antibodies can pass through effectively and when, enabling the development of safer, more effective vaccines.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The American Heart Association has released its list of top cardiovascular research for 2024, focusing on prevention, treatment and the benefits of anti-obesity medications. The research highlights improvements in assessing cardiovascular risk, identifying early prevention opportunities and treating heart failure.